Glutathione is the body's master antioxidant — a tripeptide that declines 30–50% with age. Here is what the clinical evidence says about supplementation, and which delivery forms actually raise cellular glutathione levels.
Glutathione is the most abundant intracellular antioxidant in the human body — a tripeptide (glycine, cysteine, glutamate) present in every cell, with the highest concentrations in the liver. It performs three essential functions: neutralizing reactive oxygen species, regenerating other antioxidants (vitamins C and E, CoQ10), and supporting Phase II liver detoxification. It is often called the "master antioxidant" for good reason.
The problem: glutathione levels decline 30–50% between age 40 and 70. This decline is directly linked to increased oxidative stress, reduced detoxification capacity, and impaired immune function. Supplementing glutathione to restore youthful levels is therefore a reasonable longevity target — but doing it effectively requires understanding which delivery forms actually work.
Oral glutathione has historically been considered poorly bioavailable because it is a peptide substrate for intestinal and hepatic peptidases — the same enzyme systems that break down peptides into amino acids. Early pharmacokinetic studies found that oral glutathione had limited effects on blood levels.
More recent research has revised this picture significantly:
Setria (Kyowa Hakko) glutathione: A proprietary reduced glutathione produced via fermentation. A 2015 RCT in the *European Journal of Nutrition* (n=54) found that Setria glutathione at 250 mg/day for 6 months significantly increased whole blood, erythrocyte, and plasma glutathione levels — 30–35% above baseline — compared to placebo. This is the first convincing human evidence that oral glutathione supplementation raises tissue levels.
Liposomal glutathione: Encapsulating glutathione in phospholipid vesicles protects it from gut peptidases and facilitates direct cellular absorption. A 2018 study in the *European Journal of Clinical Nutrition* found that liposomal glutathione raised plasma glutathione by 40% over 4 weeks — superior to non-encapsulated glutathione at the same dose.
S-Acetylglutathione: The acetyl group protects the thiol group from oxidation and hydrolysis in the gut, with evidence suggesting superior stability and bioavailability compared to reduced glutathione.
Rather than supplementing glutathione directly, the precursor strategy targets the rate-limiting step in glutathione synthesis. Cysteine availability is the primary bottleneck — N-Acetylcysteine (NAC) provides cysteine in a stable, bioavailable form. Clinical trials consistently show NAC raises intracellular glutathione levels.
More recently, GlyNAC (glycine + NAC) has emerged as a compelling formulation. A 2021 RCT (Sekhar et al., *Journal of Nutrition*) in older adults found that GlyNAC supplementation for 24 weeks corrected glutathione deficiency, reduced oxidative stress markers, improved mitochondrial function, and showed improvements on multiple aging biomarkers. A 2022 follow-up in older adults showed improvements in strength, gait speed, cognition, and body composition.
For budget-conscious supplementation: NAC 600 mg/day raises intracellular glutathione effectively and costs under $15/month.
For the most direct supplementation: Setria-brand reduced glutathione is the only oral form with human RCT evidence for blood level increases.
For maximum bioavailability: Liposomal glutathione delivers the highest plasma peaks and cellular absorption.
For aging adults with multiple goals: GlyNAC is the most evidence-rich combination for correcting age-related glutathione deficiency and improving functional outcomes.
Note: IV glutathione (available at some longevity clinics) produces the highest plasma levels but requires clinical administration and is cost-prohibitive for routine use.